Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Koopmans

Showing results (81-90 of 328) with videos related to

Pageof 33
Sort By:
Cancer Chemotherapy and Pharmacology|June 10, 1998
Apoptosis- and necrosis-inducing potential of cladribine, cytarabine, cisplatin, and 5-fluorouracil in vitro: a quantitative pharmacodynamic modelH J Guchelaar, I Vermes, R P Koopmans, et al.
Therapeutic Drug Monitoring|September 24, 2004
Therapeutic drug monitoring of nelfinavir in pregnancy: a case reportDavid M Burger, Karin J T Grintjes, Fred K Lotgering, et al.
Clinical Pharmacokinetics|October 1, 1995
Pharmacokinetic-pharmacodynamic modelling as applied to bronchial asthmaR P Koopmans, R E Jonkers, M C Braat, et al.
Fundamental & Clinical Pharmacology|June 14, 2003
Two novel methods for the determination of CYP1A2 activity using the paraxanthine/caffeine ratioLous J A E Doude van Troostwijk, Richard P Koopmans, Henk-Jan Guchelaar
Therapeutic Drug Monitoring|July 27, 2005
TDM: therapeutic drug measuring or therapeutic drug monitoring?Jacqueline A H Droste, Peter P Koopmans, Yechiel A Hekster, et al.
Nederlands Tijdschrift Voor Geneeskunde|August 5, 2005
[Clinical reasoning and decision making in practice: a 30-year-old man with unexplained coma]B J H van den Born, W Hart, R P Koopmans, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 13, 2024
Longitudinal Image Data for Outcome ModelingJ E van Timmeren, J Bussink, P Koopmans, et al.
The Netherlands Journal of Medicine|February 3, 2005
Highly active antiretroviral therapy for HIV infection: lessons for the futureD M Burger, A J A M van der Ven, P P Koopmans
Pharmaceutisch Weekblad. Scientific Edition|August 21, 1992
Current status of interferon alpha in the treatment of chronic hepatitis BJ B Braken, P P Koopmans, I P Van Munster, et al.
Lancet (London, England)|November 30, 2000
Surrogate endpoints for new colorectal cancer drugsA Croockewit, J Schellens, H van Bronswijk, et al.
Pageof 33

Showing results (81-90 of 328) with videos related to

Sort By:
Pageof 33
Cancer Chemotherapy and Pharmacology|June 10, 1998
Apoptosis- and necrosis-inducing potential of cladribine, cytarabine, cisplatin, and 5-fluorouracil in vitro: a quantitative pharmacodynamic modelH J Guchelaar, I Vermes, R P Koopmans, et al.
Therapeutic Drug Monitoring|September 24, 2004
Therapeutic drug monitoring of nelfinavir in pregnancy: a case reportDavid M Burger, Karin J T Grintjes, Fred K Lotgering, et al.
Clinical Pharmacokinetics|October 1, 1995
Pharmacokinetic-pharmacodynamic modelling as applied to bronchial asthmaR P Koopmans, R E Jonkers, M C Braat, et al.
Fundamental & Clinical Pharmacology|June 14, 2003
Two novel methods for the determination of CYP1A2 activity using the paraxanthine/caffeine ratioLous J A E Doude van Troostwijk, Richard P Koopmans, Henk-Jan Guchelaar
Therapeutic Drug Monitoring|July 27, 2005
TDM: therapeutic drug measuring or therapeutic drug monitoring?Jacqueline A H Droste, Peter P Koopmans, Yechiel A Hekster, et al.
Nederlands Tijdschrift Voor Geneeskunde|August 5, 2005
[Clinical reasoning and decision making in practice: a 30-year-old man with unexplained coma]B J H van den Born, W Hart, R P Koopmans, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 13, 2024
Longitudinal Image Data for Outcome ModelingJ E van Timmeren, J Bussink, P Koopmans, et al.
The Netherlands Journal of Medicine|February 3, 2005
Highly active antiretroviral therapy for HIV infection: lessons for the futureD M Burger, A J A M van der Ven, P P Koopmans
Pharmaceutisch Weekblad. Scientific Edition|August 21, 1992
Current status of interferon alpha in the treatment of chronic hepatitis BJ B Braken, P P Koopmans, I P Van Munster, et al.
Lancet (London, England)|November 30, 2000
Surrogate endpoints for new colorectal cancer drugsA Croockewit, J Schellens, H van Bronswijk, et al.
Pageof 33